Clinical Trial

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 10, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-01; most recent amendment 2025-01-08.
Status change: Not Yet Recruiting → Recruiting 2025-01-08
Trial Details
NCT Number NCT06492005
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Triple-Negative Breast Cancer
Enrollment 160 participants
Start Date 2024-07-26
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-01-10